Study of CD123 (interleukin-3 receptor alpha Chain) and nuclear factor kappa B in adult acute myeloid leukemia patients

Background: The genomic alterations in acute myeloid leukemia (AML) affect the function of signaling molecules, transcription factors, and growth factor receptors besides they influence the response to treatment. Interleukin-3 receptor alpha chain (CD123) is overexpressed in about 45% of AML, this p...

Full description

Bibliographic Details
Main Authors: Inas Asfour, Soha Yoyssef, Maryse Ayoub, Nevine Moustafa, Hani Ayash, Tussneem Elhassan, Ghada M ElGohary
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2014-01-01
Series:Journal of Applied Hematology
Subjects:
Online Access:http://www.jahjournal.org/article.asp?issn=1658-5127;year=2014;volume=5;issue=4;spage=151;epage=155;aulast=Asfour
_version_ 1819104186037436416
author Inas Asfour
Soha Yoyssef
Maryse Ayoub
Nevine Moustafa
Hani Ayash
Tussneem Elhassan
Ghada M ElGohary
author_facet Inas Asfour
Soha Yoyssef
Maryse Ayoub
Nevine Moustafa
Hani Ayash
Tussneem Elhassan
Ghada M ElGohary
author_sort Inas Asfour
collection DOAJ
description Background: The genomic alterations in acute myeloid leukemia (AML) affect the function of signaling molecules, transcription factors, and growth factor receptors besides they influence the response to treatment. Interleukin-3 receptor alpha chain (CD123) is overexpressed in about 45% of AML, this phenomenon was associated with high blast cell counts at diagnosis, with a worse prognosis. The transcription nuclear factor kappa B (NF-κB) can intervene in oncogenesis through its capacity to regulate the expression of a large number of genes that regulate apoptosis, cell proliferation, and differentiation. This study aimed to assess the relationship between CD123 expression and NF-κB level, in adult patients with AML at presentation and after induction therapy together with a well-known diagnostic and prognostic factors in AML. The study was conducted on forty adult newly diagnosed AML (group A) as well as twenty adult subjects who were hemato-oncologically free, as a control group (group B). Bone marrow (BM) examination and immunophenotyping by flow cytometry (FCM) on BM aspirate, for CD123 and quantitation of NF-κB in BM samples using ELISA (at three levels: Plasma, cytoplasmic and nuclear fraction of blasts, accordingly cytoplasmic/nuclear ratio) were performed for all studied subjects. In addition, levels of CD123 on blast cells and NF-κB were evaluated at D28 for remitted and resistant cases. All patients were positive for CD123 by FCM on BM blasts at time of diagnosis. The median cell counts expressing CD123 was 52.9 (34.4-75.6). Positive expression of CD123 was ≥20%, while in the control subjects CD123 expression was 25.1 (16.9-59.3), with significant decrease in CD123 expression after therapy, Besides, CD123 was also significantly higher in resistant patients compared to remitted patients (P = 0.009). As regard NF-κB, it was significantly higher in AML patients compared to control subjects at the three levels (plasma - cytoplasmic fraction - nuclear fraction) with a significant decrease after therapy. It was found that those NF-κB levels detected at follow-up (D28) on BM expression were significantly higher in resistant patients compared to remitted patients. While only The follow-up results, showed a highly significant positive correlation between CD123 expression on blast cells level and NF-κB plasma level alone (r = 0.587, P = 0.007) while there was not any correlation between CD123 and other two NF-κB levels neither at diagnosis nor at the follow-up. Conclusion: These data suggest that the correlation between CD123 and NF-κB was identified in variable results, and further elucidation of this role is likely to have important implications.
first_indexed 2024-12-22T02:02:21Z
format Article
id doaj.art-877619e81efe412da466a1e1db6e109e
institution Directory Open Access Journal
issn 1658-5127
language English
last_indexed 2024-12-22T02:02:21Z
publishDate 2014-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Journal of Applied Hematology
spelling doaj.art-877619e81efe412da466a1e1db6e109e2022-12-21T18:42:38ZengWolters Kluwer Medknow PublicationsJournal of Applied Hematology1658-51272014-01-015415115510.4103/1658-5127.146950Study of CD123 (interleukin-3 receptor alpha Chain) and nuclear factor kappa B in adult acute myeloid leukemia patientsInas AsfourSoha YoyssefMaryse AyoubNevine MoustafaHani AyashTussneem ElhassanGhada M ElGoharyBackground: The genomic alterations in acute myeloid leukemia (AML) affect the function of signaling molecules, transcription factors, and growth factor receptors besides they influence the response to treatment. Interleukin-3 receptor alpha chain (CD123) is overexpressed in about 45% of AML, this phenomenon was associated with high blast cell counts at diagnosis, with a worse prognosis. The transcription nuclear factor kappa B (NF-κB) can intervene in oncogenesis through its capacity to regulate the expression of a large number of genes that regulate apoptosis, cell proliferation, and differentiation. This study aimed to assess the relationship between CD123 expression and NF-κB level, in adult patients with AML at presentation and after induction therapy together with a well-known diagnostic and prognostic factors in AML. The study was conducted on forty adult newly diagnosed AML (group A) as well as twenty adult subjects who were hemato-oncologically free, as a control group (group B). Bone marrow (BM) examination and immunophenotyping by flow cytometry (FCM) on BM aspirate, for CD123 and quantitation of NF-κB in BM samples using ELISA (at three levels: Plasma, cytoplasmic and nuclear fraction of blasts, accordingly cytoplasmic/nuclear ratio) were performed for all studied subjects. In addition, levels of CD123 on blast cells and NF-κB were evaluated at D28 for remitted and resistant cases. All patients were positive for CD123 by FCM on BM blasts at time of diagnosis. The median cell counts expressing CD123 was 52.9 (34.4-75.6). Positive expression of CD123 was ≥20%, while in the control subjects CD123 expression was 25.1 (16.9-59.3), with significant decrease in CD123 expression after therapy, Besides, CD123 was also significantly higher in resistant patients compared to remitted patients (P = 0.009). As regard NF-κB, it was significantly higher in AML patients compared to control subjects at the three levels (plasma - cytoplasmic fraction - nuclear fraction) with a significant decrease after therapy. It was found that those NF-κB levels detected at follow-up (D28) on BM expression were significantly higher in resistant patients compared to remitted patients. While only The follow-up results, showed a highly significant positive correlation between CD123 expression on blast cells level and NF-κB plasma level alone (r = 0.587, P = 0.007) while there was not any correlation between CD123 and other two NF-κB levels neither at diagnosis nor at the follow-up. Conclusion: These data suggest that the correlation between CD123 and NF-κB was identified in variable results, and further elucidation of this role is likely to have important implications.http://www.jahjournal.org/article.asp?issn=1658-5127;year=2014;volume=5;issue=4;spage=151;epage=155;aulast=AsfourAcute myeloid leukemiaCD123nuclear factor kappa B
spellingShingle Inas Asfour
Soha Yoyssef
Maryse Ayoub
Nevine Moustafa
Hani Ayash
Tussneem Elhassan
Ghada M ElGohary
Study of CD123 (interleukin-3 receptor alpha Chain) and nuclear factor kappa B in adult acute myeloid leukemia patients
Journal of Applied Hematology
Acute myeloid leukemia
CD123
nuclear factor kappa B
title Study of CD123 (interleukin-3 receptor alpha Chain) and nuclear factor kappa B in adult acute myeloid leukemia patients
title_full Study of CD123 (interleukin-3 receptor alpha Chain) and nuclear factor kappa B in adult acute myeloid leukemia patients
title_fullStr Study of CD123 (interleukin-3 receptor alpha Chain) and nuclear factor kappa B in adult acute myeloid leukemia patients
title_full_unstemmed Study of CD123 (interleukin-3 receptor alpha Chain) and nuclear factor kappa B in adult acute myeloid leukemia patients
title_short Study of CD123 (interleukin-3 receptor alpha Chain) and nuclear factor kappa B in adult acute myeloid leukemia patients
title_sort study of cd123 interleukin 3 receptor alpha chain and nuclear factor kappa b in adult acute myeloid leukemia patients
topic Acute myeloid leukemia
CD123
nuclear factor kappa B
url http://www.jahjournal.org/article.asp?issn=1658-5127;year=2014;volume=5;issue=4;spage=151;epage=155;aulast=Asfour
work_keys_str_mv AT inasasfour studyofcd123interleukin3receptoralphachainandnuclearfactorkappabinadultacutemyeloidleukemiapatients
AT sohayoyssef studyofcd123interleukin3receptoralphachainandnuclearfactorkappabinadultacutemyeloidleukemiapatients
AT maryseayoub studyofcd123interleukin3receptoralphachainandnuclearfactorkappabinadultacutemyeloidleukemiapatients
AT nevinemoustafa studyofcd123interleukin3receptoralphachainandnuclearfactorkappabinadultacutemyeloidleukemiapatients
AT haniayash studyofcd123interleukin3receptoralphachainandnuclearfactorkappabinadultacutemyeloidleukemiapatients
AT tussneemelhassan studyofcd123interleukin3receptoralphachainandnuclearfactorkappabinadultacutemyeloidleukemiapatients
AT ghadamelgohary studyofcd123interleukin3receptoralphachainandnuclearfactorkappabinadultacutemyeloidleukemiapatients